VANCOUVER, BRITISH COLUMBIA--(Marketwire - February 21, 2008) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that three abstracts regarding the Company’s lead drug candidate CTCE-9908 were accepted by the American Association for Cancer Research (“AACR”) for presentation at their Annual Meeting being held in San Diego, California, April 13 - 16, 2008.
